Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.

Although final exploratory analyses of OS (median OS, 75.0 vs 64.7 weeks; HR 0.87, 95% CI 0.71–1.08, P = 0.210) showed a trend toward a survival advantage with lapatinib plus capecitabine, premature termination of enrollment and subsequent crossover resulted in insufficient power to detect significant differences. 43 T-DM1 is an antibody–drug conjugate incorporating the HER2-targeted antitumor properties of trastuzumab wit

also in 53,322 other papers